A recently approved law in the United States has caused a major shock across the global medical cannabis industry. The regulation redefines the standards for cannabis derived products, restricting compounds that were previously legal and widely used in medical treatments as well as in the commercial market.
The change has raised alarms in several Latin American countries, including Colombia, that depend heavily on the export of extracts and derivatives. The new classification could leave dozens of products out of compliance with updated cannabinoid limits, affecting thousands of producers and laboratories.
In addition, this regulatory shift now demands stricter purity controls and certification requirements, forcing the industry to adapt quickly in order to maintain a presence in one of the world’s most influential markets.
What does this law mean for patients and producers?
For patients, it may temporarily reduce the availability of certain products. For producers, it represents the need to meet tighter standards to remain competitive internationally.
